When Do GLP-1 Generics Arrive? The Complete Patent Cliff Analysis

Novo Nordisk holds 320 US patent applications and 154 granted patents related to semaglutide. Eli Lilly's tirzepatide core patent doesn't expire until January 2036. The first generic GLP-1 — liraglutide — was approved in December 2024. Here's the full timeline for what comes next.

The most common question from patients paying $1,000+ per month for brand-name GLP-1 drugs: when will there be a generic? The answer depends on which drug you're asking about, which country you're in, and how aggressively generic manufacturers challenge the patent thickets that protect these products.

The first domino has already fallen. In December 2024, the FDA approved a generic version of liraglutide (Victoza) made by Hikma Pharmaceuticals, for type 2 diabetes. But liraglutide is the oldest GLP-1, with far less market demand than semaglutide or tirzepatide. The drugs patients actually want — generic Ozempic, generic Wegovy, generic Mounjaro, generic Zepbound — remain years away in the United States.

Semaglutide: The Patent Landscape

Novo Nordisk has built an extensive patent thicket around semaglutide. According to I-MAK analysis, the company has filed 320 US patent applications and been granted 154 patents related to Ozempic, Wegovy, and Rybelsus. The key patents include composition-of-matter patents protecting the semaglutide molecule itself (expiring December 2031), formulation patents covering stability and delivery (expiring through 2031–2033), and method-of-treatment patents covering specific indications (various expiry dates through 2033).

The critical date is December 5, 2031 — when the '343 compound patent expires. Mylan filed an inter partes review (IPR) challenge against this patent in 2023 and lost, which was a major blow to early generic entry hopes. Novo Nordisk has since settled with Mylan, Sun Pharmaceuticals, Dr. Reddy's, and Apotex on negotiated entry dates that likely fall between December 2031 and June 2033.

Tirzepatide: Longer Protection

Eli Lilly's tirzepatide compound patent (US '780) was filed in 2015 and expires in January 2036. Additional formulation patents don't expire until June 2039. Unless those formulation patents are successfully challenged, generic tirzepatide is realistically a late-2030s prospect in the United States.

The International Picture

Outside the US, the timeline is more aggressive. Novo Nordisk's semaglutide patent in China expires in 2026, making China potentially the first major market with generic semaglutide. India has a similar timeline. Generic-drug manufacturers including companies in China, India, and South Korea are actively developing semaglutide and tirzepatide production capabilities in anticipation.

International generics will not directly help US patients — importation is illegal without FDA approval — but they signal that global competition and price pressure are coming years before US patent expiry.

Biosimilar vs. Traditional Generic

An important technical distinction: semaglutide and tirzepatide are peptide drugs, not traditional small-molecule chemicals. What eventually arrives may be classified as a biosimilar or follow-on biologic rather than a traditional generic. Biosimilar approval requires its own clinical demonstration of pharmacokinetic, pharmacodynamic, and immunogenicity similarity — a more expensive and time-consuming process than traditional generic approval. This means the post-patent competitive landscape may be slower to develop than for typical small-molecule drugs.